Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Withdrawn Phase 2 Interventional

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

NCT04655807
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-64304500, Placebo, Adalimumab, Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

NCT00421707
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
GW876008, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Sherwood, Arkansas • Concord, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Of GW679769 In Major Depressive Disorder

NCT00102492
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

NCT00913744
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
Interventions
Ocriplasmin, Sham injection
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Beverly Hills, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

NCT02117934
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
8,374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

NCT02453334
View directory record Official record
Conditions
Cancer and Chemotherapy Related Anemia
Interventions
Injectafer, Normal Saline
Drug · Other
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Corona, California • Fountain Valley, California • Riverside, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

NCT03320434
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
PRT-2761 0.5%, PRT-2761 1%, Patanol, Pred-forte, PRT-2761 0%
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 25, 2026, 5:59 PM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

NCT07395232
View directory record Official record
Conditions
Atopic Keratoconjunctivitis
Interventions
DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
10 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Immediate vs Delayed Loading of Two Implants Supporting a Mandibular Over Denture

NCT01949298
View directory record Official record
Conditions
Implant Survival Using Immediate Loading Protocol
Interventions
dental implant placement
Procedure
Lead sponsor
UConn Health
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 25, 2026, 5:59 PM EDT
Terminated Phase 3 Interventional Results available

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

NCT02829814
View directory record Official record
Conditions
Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases, Musculoskeletal Diseases
Interventions
TNX-102 SL Tablet, 2.8 mg, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 25, 2026, 5:59 PM EDT
Terminated Phase 3 Interventional

Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

NCT02950233
View directory record Official record
Conditions
Pain, Postoperative
Interventions
NMDA active, Steroid active, NMDA placebo, Steroid placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 25, 2026, 5:59 PM EDT
Not yet recruiting Not applicable Interventional

Impact of Loss Aversion Messaging and Anticipated Regret for Inaction on Exercise Adherence in Older Adults

NCT07540052
View directory record Official record
Conditions
Mobility Disability, Walking Difficulty
Interventions
Brief Daily At-Home Strength Training Program, Loss Aversion Messaging, Standard Adherence Reminder Messaging
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

NCT01436500
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Ifetroban Injection, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

NCT00115999
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

NCT03436199
View directory record Official record
Conditions
Walking Impairment, Multiple Sclerosis
Interventions
ADS-5102, 137 mg, ADS-5102, 274 mg, Placebo
Drug · Other
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
78
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT03701763
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast (CC-10004), Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 25, 2026, 5:59 PM EDT
Withdrawn Phase 2 Interventional

ACZ885 in Type 1 Diabetes Mellitus

NCT01322321
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Type 1
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

NCT04732221
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Interventions
Frespaciguat, Placebo to Frespaciguat
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

NCT02485704
View directory record Official record
Conditions
Scabies
Interventions
spinosad topical suspension, 0.9%, Placebo
Drug · Other
Lead sponsor
ParaPRO LLC
Industry
Eligibility
4 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Long Beach, California • Kissimmee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

INDV-2000 First in Human

NCT04413552
View directory record Official record
Conditions
Opioid Dependence
Interventions
INDV-2000, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

NCT06393452
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
PP405 0.05% Topical Gel, Topical Vehicle Gel
Drug
Lead sponsor
Pelage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 5:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

MLD10 in the Prevention of Migraine in Adults

NCT02322333
View directory record Official record
Conditions
Migraine
Interventions
MLD10, Placebo
Drug
Lead sponsor
Pharmalyte Solutions LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Carlsbad, California • San Francisco, California • Oviedo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 25, 2026, 5:59 PM EDT